We are working
tirelessly to bring the
best science forward.
BrainChild Bio is a clinical-stage biotechnology company leading the field in the development of CAR T-cell therapies for tumors in the central nervous system (CNS). We are kids-first, prioritizing pediatric brain tumors, with a pipeline that extends our technology platform to adult indications, including glioblastoma and brain metastases.
“For far too long, children and young adults have been deprioritized for commercialized medicines, and families have been left with few options. BrainChild Bio can do both — prioritize these patients, while rapidly advancing new science that can be applied to a wider population and change the course of how cancers are treated.”
Steven Brugger
Chief Executive Officer